Floatz logo

Mtm-H-001

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Cancer Institute and Hospital, Chinese Academy of Medical SciencesN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

270 Active assets in the Lymphoma, Large B-Cell, Diffuse (DLBCL) cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Mtm-H-001 is also rated in:

mantle cell lymphomaDormant
D
Indicative ·
30 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
D
Indicative ·
30 / 100
View asset →
follicular lymphomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →